MARATTO

article · Ibn AL- Haitham Journal For Pure and Applied Science

Synthesis and Spectral Investigation of Mixed Schiff Base and L-Leucine Complexes and their Biological Activity

2026Open accessSohag University

Abstract

In this study, transition complexes of Fe(III), Zn(II), La(III), Ce(III), and Pr(III) with a Schiff base ligand (L), which is derived from 3-hydroxybenzaldehyde and sulfamethoxazole, as the primary ligand, and L-Leucinate as a secondary ligand. The bonding mode of the Schiff base has been confirmed through a range of techniques, including infrared, UV-visible (UV-Vis), carbon and proton nuclear magnetic resonance spectroscopy, mass spectrometry, and elemental analysis. All complexes were characterized by elemental analysis, conductivity measurements, and spectroscopic techniques, including UV-Vis and Fourier transform infrared spectroscopy. A thorough discussion is provided on the structural and bonding features of the mixed ligand complexes formed from the Schiff base (L) and L-Leucine with ions [Fe (III), Zn(II), La(III), Ce(III), and Pr(III)], based on results from various research studies. Additionally, the antimicrobial activity of these complexes was evaluated against two Gram-positive and two Gram-negative bacterial strains. Furthermore, antifungal activity against Candida was evaluated, with tetracycline as the reference.

Research topics

  • Metal complexes synthesis and properties
  • Inorganic and Organometallic Chemistry
  • Lanthanide and Transition Metal Complexes

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.30526/39.2.4340

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.